T-DM1 Found to Prolong Progression-Free Survival in Patients with HER2+ Metastatic Breast Cancer

Share this content:
T-DM1 Found to Prolong Progression-Free Survival in Patients with HER2+ Metastatic Breast Cancer
T-DM1 Found to Prolong Progression-Free Survival in Patients with HER2+ Metastatic Breast Cancer

CME

Program Description:

The experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC) previously treated with a taxane and trastuzumab, according to primary results from the randomized phase 3 EMILIA trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Evaluate the efficacy and safety of the experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) among patients with HER2+ locally advanced or metastatic breast cancer.

  • Develop protocols to increase PFS among patients with HER2+ locally advanced or metastatic breast cancer who are inadequately responsive to established treatment protocols.

Click Next to begin the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs